Otero Jose Manuel 4

What Happened

• Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics (LXEO), acquired 5,930 shares of company common stock on 2026-03-13 at $2.64 per share, for a total value of approximately $15,679. The filing classifies this as an award/acquisition under the company's 2023 Employee Stock Purchase Plan (ESPP).

Key Details

• Transaction date: 2026-03-13; Filing date: 2026-03-17 (filed within the standard reporting window).
• Price: $2.64 per share; Shares acquired: 5,930; Total value: ~$15,679.
• Footnote F1: Reported voluntarily under the 2023 ESPP; transaction is exempt under Rule 16b-3(c) and 16b-3(d).
• Footnote F2: Filing notes holdings include 104,216 restricted stock units (RSUs).
• Filing type: Form 4 (insider report). No late-filing flag was indicated.

Context

• This was an acquisition through the company ESPP (an employee purchase), which is a routine way employees obtain stock and is exempt under certain Section 16 rules. The dollar amount is modest relative to typical insider trades; factual reporting of this purchase does not by itself imply management sentiment.